+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Small-Molecule APIs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Small-Molecule APIs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Sale

Small-Molecule APIs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5532977
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Small-Molecule APIs Market grew from USD 197.35 billion in 2024 to USD 212.05 billion in 2025. It is expected to continue growing at a CAGR of 7.31%, reaching USD 301.42 billion by 2030.

Effective small-molecule active pharmaceutical ingredients (APIs) remain the backbone of modern therapeutics, driving innovation across a spectrum of disease areas. As research and development efforts intensify, manufacturers and stakeholders must navigate a landscape defined by rapid scientific advances, shifting regulatory frameworks, and evolving supply chain dynamics. This introduction highlights how precision synthesis, strategic partnerships, and adaptive manufacturing approaches are reshaping production paradigms. By understanding the core drivers-from technological breakthroughs in chemical synthesis and microbial fermentation to the growing emphasis on generic competition-industry leaders can position themselves to capitalize on emerging growth corridors. The following sections will explore transformative shifts, tariff impacts, segmentation nuances, regional footprints, competitive intelligence, and actionable strategies to ensure sustained excellence in the small-molecule API sector.

Transformative Shifts Reshaping the Small-Molecule API Landscape

In recent years, the small-molecule API space has undergone transformative realignment driven by several pivotal shifts. First, the integration of continuous processes alongside traditional batch synthesis has accelerated throughput, reduced operational footprints, and enhanced quality control. Simultaneously, recombinant technology and microbial fermentation platforms have broadened the scope of half-small molecules, enabling more sustainable production pathways and unlocking complex natural analogues. Meanwhile, the rise of personalized medicine has intensified demand for branded full small molecules while spurring generic manufacturers to optimize cost structures. Regulatory agencies worldwide have also adopted more streamlined pathways for biosimilars and generics, fostering heightened competition and greater patient access. Finally, digitalization-from advanced process analytics to AI-powered formulation design-has accelerated decision-making and risk mitigation. Together, these dynamics are redefining how small-molecule APIs are discovered, manufactured, and brought to market, setting the stage for future growth and innovation.

Cumulative Impact of United States Tariffs 2025 on Supply and Pricing

As the United States implemented new tariff measures in early 2025, the small-molecule API industry encountered significant cost and supply implications. Tariffs introduced on select imported precursors and intermediates triggered supply chain recalibrations, prompting firms to re-evaluate sourcing strategies. Some manufacturers responded by near-shoring key chemical synthesis operations domestically, while others diversified supplier portfolios across Southeast Asia and Eastern Europe. The direct cost increases on critical raw materials led to a reconfiguration of pricing models, with companies absorbing a portion of expenses to preserve market share. In parallel, regulatory authorities expedited reviews for domestic API facilities to mitigate potential shortages, catalyzing investment in expanded production capacities. Although tariff-induced disruptions created near-term pricing pressures, they also stimulated resilience-building measures such as dual-sourcing agreements and enhanced inventory buffers. Collectively, these adaptations have strengthened the sector’s preparedness for future geopolitical and trade uncertainties.

Key Segmentation Insights Driving Market Dynamics

Deeper insights emerge when examining the market through multiple segmentation lenses. When categorized by molecule type, full small molecules bifurcate into branded entities commanding premium pricing and generic counterparts driving volume growth, while half-small molecules split between naturally originated compounds obtained via microbial fermentation and synthetically modified analogues produced through recombinant and chemical pathways. Therapeutic application segmentation further reveals that demand for cardiovascular APIs-spanning treatments for coronary heart disease, hypertension, and stroke-remains robust, even as neurological disorder APIs targeting Alzheimer’s, epilepsy, and Parkinson’s Disease gain traction. Oncology segments are equally nuanced: breast cancer therapies dominate volume, with colorectal cancer APIs differentiated into colon and rectal cancer portfolios, complemented by a growing lung cancer pipeline. Manufacturing technology insights show that biotech processes, which include both fermentation and recombinant techniques, coexist with batch and continuous chemical synthesis, and are increasingly integrated within hybrid process frameworks. Delivery method perspectives highlight injectable formats in syringes and vials, oral modalities in capsules and tablets, and topical creams and gels. Finally, end-user segmentation underscores that contract manufacturing organizations-ranging from full-service to specialized operations-pharmaceutical companies, whether branded or generic manufacturers, and research institutions comprising government bodies and private institutes each play distinct roles, while sales channel analysis illuminates direct B2B and institutional engagements alongside distributor networks in hospital and retail settings and the rapidly expanding e-pharmacy sector.

Key Regional Insights Shaping Production and Distribution

Regional performance varies significantly across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established infrastructure and proximity to lead innovators underpin strong capacities for both branded and generic full small molecules, bolstered by direct investments in continuous manufacturing and recombinant platforms. Regulatory harmonization initiatives across North and South America further streamline cross-border API distribution. Across Europe, Middle East & Africa, stringent pharmacopoeial standards and early adoption of hybrid process technologies drive quality differentiation, while strategic partnerships with emerging hubs in the Middle East enhance supply resilience. Meanwhile, Asia-Pacific exhibits rapid expansion in chemical synthesis throughput, particularly within China and India, where cost efficiencies support both low-cost generics and advanced biotech processes. Additionally, an increasing number of local CMOs are broadening service portfolios to meet growing regional demand for injectable, oral, and topical APIs. These geographic trends underscore the importance of tailored regional strategies to optimize production footprints and regulatory compliance efforts.

Key Company Insights and Competitive Intelligence

Competitive intensity in the small-molecule API sector is underscored by the strategic initiatives of leading organizations. AbbVie Inc. and AstraZeneca PLC continue to invest in advanced recombinant and continuous synthesis capabilities, while companies like Agilent Technologies, Inc. and Bio-Rad Laboratories, Inc. support analytical and quality assurance enhancements that accelerate time-to-market. Albemarle Corporation and Lonza Group AG have prioritized hybrid process integration, blending microbial fermentation with chemical routes. Contract manufacturing remains strong for firms such as Cambrex Corporation by Permira funds and Charles River Laboratories International, Inc., whereas specialized biotech API services flourish at Alacrita Holdings Limited and Deciphera Pharmaceuticals, Inc. Major pharma players including Bristol-Myers Squibb, GlaxoSmithKline PLC, and Merck KGaA leverage internal synthesis pipelines alongside external partnerships to optimize branded molecule production. Generic and high-volume APIs are dominated by Aurobindo Pharma Limited, Teva Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories Ltd., supported by Pfizer, Inc. and Gilead Sciences, Inc. for niche oncology and antiviral APIs. Aspen Group and Bachem Holding AG focus on high-purity and custom synthesis, while Koninklijke DSM N.V. and Boehringer Ingelheim GmbH drive innovation in targeted delivery formats. These companies’ strategic investments and collaborative ventures define the competitive contours of the industry.

Actionable Recommendations for Industry Leaders

To navigate this complex environment, industry leaders should adopt a multi-pronged approach. First, investing in hybrid manufacturing technologies that integrate continuous synthesis and microbial fermentation can reduce costs, enhance flexibility, and improve sustainability metrics. Second, establishing dual sourcing strategies for critical intermediates-leveraging both near-shore and offshore capacities-can mitigate geopolitical risks and tariff impacts. Third, pursuing value-based partnerships with analytical service providers accelerates quality assurance and regulatory compliance, especially for injectable and high-potency APIs. Fourth, expanding e-pharmacy and specialized distributor channels ensures broader market access, particularly for generic and high-volume products. Fifth, fostering collaborations with academic and private research institutions can expedite the discovery of novel half-small molecules and targeted oncology compounds. By aligning R&D priorities with evolving therapeutic trends and regulatory requirements, organizations can achieve operational excellence while sustaining competitive differentiation.

Conclusion: Embracing Innovation and Resilience

As the small-molecule API sector continues its trajectory of innovation and globalization, stakeholders must remain agile and forward-looking. Technological convergence-combining chemical synthesis, biotech processes, and digital analytics-will drive next-generation capabilities. Resilient supply chains, fortified through diversified sourcing and regional expansion, will safeguard continuity against trade and geopolitical headwinds. Strategic collaborations across the value chain will unlock efficiencies and foster rapid translation from discovery to commercialization. Ultimately, success in this dynamic ecosystem hinges on a balanced approach that integrates robust manufacturing platforms, rigorous quality standards, and adaptive market strategies.

Market Segmentation & Coverage

This research report categorizes the Small-Molecule APIs Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Full Small Molecules
    • Branded Molecules
    • Generic Molecules
  • Half-Small Molecules
    • Naturally Originated
    • Synthetically Modified
  • Cardiovascular
    • Coronary Heart Disease
    • Hypertension
    • Stroke
  • Neurological Disorders
    • Alzheimer's Disease
    • Epilepsy
    • Parkinson's Disease
  • Oncology
    • Breast Cancer
    • Colorectal Cancer
      • Colon Cancer
      • Rectal Cancer
    • Lung Cancer
  • Biotech Processes
    • Microbial Fermentation
    • Recombinant Technology
  • Chemical Synthesis
    • Batch Processes
    • Continuous Processes
  • Hybrid Processes
  • Injectable Delivery
    • Syringes
    • Vials
  • Oral Delivery
    • Capsules
    • Tablets
  • Topical Applications
    • Creams
    • Gels
  • Contract Manufacturing Organizations
    • Full-Service CMOs
    • Specialized CMOs
  • Pharmaceutical Companies
    • Branded Drug Manufacturers
    • Generic Drug Manufacturers
  • Research Institutions
    • Government Research Bodies
    • Private Research Institutes
  • Direct Sales
    • B2B Sales
    • Institutional Sales
  • Distributor Sales
    • Hospital Chains
    • Retail Distribution
  • E-Pharmacy Sales

This research report categorizes the Small-Molecule APIs Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Small-Molecule APIs Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Agilent Technologies, Inc.
  • Alacrita Holdings Limited
  • Albemarle Corporation
  • Aspen Group
  • Astrazeneca PLC
  • Aurobindo Pharma Limited
  • Bachem Holding AG
  • Bio-Rad Laboratories, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Cambrex Corporation by Permira funds
  • Carlyle Group
  • Charles River Laboratories International, Inc.
  • Deciphera Pharmaceuticals, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd,
  • Gilead Sciences, Inc
  • GlaxoSmithKline PLC
  • Koninklijke DSM N.V.
  • Lonza Group AG
  • Merck KGaA
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Small-Molecule APIs Market, by Molecule Type
8.1. Introduction
8.2. Full Small Molecules
8.2.1. Branded Molecules
8.2.2. Generic Molecules
8.3. Half-Small Molecules
8.3.1. Naturally Originated
8.3.2. Synthetically Modified
9. Small-Molecule APIs Market, by Therapeutic Application
9.1. Introduction
9.2. Cardiovascular
9.2.1. Coronary Heart Disease
9.2.2. Hypertension
9.2.3. Stroke
9.3. Neurological Disorders
9.3.1. Alzheimer's Disease
9.3.2. Epilepsy
9.3.3. Parkinson's Disease
9.4. Oncology
9.4.1. Breast Cancer
9.4.2. Colorectal Cancer
9.4.2.1. Colon Cancer
9.4.2.2. Rectal Cancer
9.4.3. Lung Cancer
10. Small-Molecule APIs Market, by Manufacturing Technology
10.1. Introduction
10.2. Biotech Processes
10.2.1. Microbial Fermentation
10.2.2. Recombinant Technology
10.3. Chemical Synthesis
10.3.1. Batch Processes
10.3.2. Continuous Processes
10.4. Hybrid Processes
11. Small-Molecule APIs Market, by Delivery Method
11.1. Introduction
11.2. Injectable Delivery
11.2.1. Syringes
11.2.2. Vials
11.3. Oral Delivery
11.3.1. Capsules
11.3.2. Tablets
11.4. Topical Applications
11.4.1. Creams
11.4.2. Gels
12. Small-Molecule APIs Market, by End-User
12.1. Introduction
12.2. Contract Manufacturing Organizations
12.2.1. Full-Service CMOs
12.2.2. Specialized CMOs
12.3. Pharmaceutical Companies
12.3.1. Branded Drug Manufacturers
12.3.2. Generic Drug Manufacturers
12.4. Research Institutions
12.4.1. Government Research Bodies
12.4.2. Private Research Institutes
13. Small-Molecule APIs Market, by Sales Channel
13.1. Introduction
13.2. Direct Sales
13.2.1. B2B Sales
13.2.2. Institutional Sales
13.3. Distributor Sales
13.3.1. Hospital Chains
13.3.2. Retail Distribution
13.4. E-Pharmacy Sales
14. Americas Small-Molecule APIs Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Small-Molecule APIs Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Small-Molecule APIs Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Agilent Technologies, Inc.
17.3.3. Alacrita Holdings Limited
17.3.4. Albemarle Corporation
17.3.5. Aspen Group
17.3.6. Astrazeneca PLC
17.3.7. Aurobindo Pharma Limited
17.3.8. Bachem Holding AG
17.3.9. Bio-Rad Laboratories, Inc.
17.3.10. Boehringer Ingelheim GmbH
17.3.11. Bristol-Myers Squibb
17.3.12. Cambrex Corporation by Permira funds
17.3.13. Carlyle Group
17.3.14. Charles River Laboratories International, Inc.
17.3.15. Deciphera Pharmaceuticals, Inc.
17.3.16. Dr. Reddy’s Laboratories Ltd.
17.3.17. F. Hoffmann-La Roche Ltd,
17.3.18. Gilead Sciences, Inc
17.3.19. GlaxoSmithKline PLC
17.3.20. Koninklijke DSM N.V.
17.3.21. Lonza Group AG
17.3.22. Merck KGaA
17.3.23. Pfizer, Inc.
17.3.24. Teva Pharmaceutical Industries Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. SMALL-MOLECULE APIS MARKET MULTI-CURRENCY
FIGURE 2. SMALL-MOLECULE APIS MARKET MULTI-LANGUAGE
FIGURE 3. SMALL-MOLECULE APIS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA SMALL-MOLECULE APIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA SMALL-MOLECULE APIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. SMALL-MOLECULE APIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. SMALL-MOLECULE APIS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SMALL-MOLECULE APIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY FULL SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY BRANDED MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY GENERIC MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY FULL SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY HALF-SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY NATURALLY ORIGINATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY SYNTHETICALLY MODIFIED, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY HALF-SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY CORONARY HEART DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY COLON CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY RECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY BIOTECH PROCESSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY MICROBIAL FERMENTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY RECOMBINANT TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY BIOTECH PROCESSES, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY BATCH PROCESSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY CONTINUOUS PROCESSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY HYBRID PROCESSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY INJECTABLE DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY INJECTABLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY ORAL DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY ORAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY TOPICAL APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY TOPICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY FULL-SERVICE CMOS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY SPECIALIZED CMOS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY BRANDED DRUG MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY GOVERNMENT RESEARCH BODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY PRIVATE RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY B2B SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY INSTITUTIONAL SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY DISTRIBUTOR SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY HOSPITAL CHAINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY RETAIL DISTRIBUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY DISTRIBUTOR SALES, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL SMALL-MOLECULE APIS MARKET SIZE, BY E-PHARMACY SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY FULL SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY HALF-SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY BIOTECH PROCESSES, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY INJECTABLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY ORAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY TOPICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY DISTRIBUTOR SALES, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS SMALL-MOLECULE APIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY FULL SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY HALF-SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY BIOTECH PROCESSES, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY INJECTABLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY ORAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY TOPICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA SMALL-MOLECULE APIS MARKET SIZE, BY DISTRIBUTOR SALES, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY FULL SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY HALF-SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY BIOTECH PROCESSES, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY INJECTABLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY ORAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY TOPICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL SMALL-MOLECULE APIS MARKET SIZE, BY DISTRIBUTOR SALES, 2018-2030 (USD MILLION)
TABLE 147. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 148. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY FULL SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 149. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY HALF-SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 150. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 152. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 153. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 154. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 155. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 156. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY BIOTECH PROCESSES, 2018-2030 (USD MILLION)
TABLE 157. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 158. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 159. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY INJECTABLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 160. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY ORAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 161. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY TOPICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 162. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 164. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 165. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 166. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 168. CANADA SMALL-MOLECULE APIS MARKET SIZE, BY DISTRIBUTOR SALES, 2018-2030 (USD MILLION)
TABLE 169. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 170. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY FULL SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 171. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY HALF-SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 172. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 174. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 175. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 176. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 177. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 178. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY BIOTECH PROCESSES, 2018-2030 (USD MILLION)
TABLE 179. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 180. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 181. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY INJECTABLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 182. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY ORAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 183. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY TOPICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 184. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 185. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 186. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 187. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 188. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 190. MEXICO SMALL-MOLECULE APIS MARKET SIZE, BY DISTRIBUTOR SALES, 2018-2030 (USD MILLION)
TABLE 191. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 192. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY FULL SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 193. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY HALF-SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 197. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 198. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 199. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 200. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY BIOTECH PROCESSES, 2018-2030 (USD MILLION)
TABLE 201. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 202. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 203. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY INJECTABLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 204. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY ORAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 205. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY TOPICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 206. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 207. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 208. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 209. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 210. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 212. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY DISTRIBUTOR SALES, 2018-2030 (USD MILLION)
TABLE 213. UNITED STATES SMALL-MOLECULE APIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 214. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY FULL SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 216. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY HALF-SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 218. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 219. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 220. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 221. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 222. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 223. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY BIOTECH PROCESSES, 2018-2030 (USD MILLION)
TABLE 224. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 225. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 226. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY INJECTABLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 227. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY ORAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 228. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY TOPICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 229. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY DISTRIBUTOR SALES, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC SMALL-MOLECULE APIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 237. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 238. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY FULL SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 239. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY HALF-SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 240. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 241. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 242. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 243. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 244. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 245. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 246. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY BIOTECH PROCESSES, 2018-2030 (USD MILLION)
TABLE 247. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 248. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 249. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY INJECTABLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 250. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY ORAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 251. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY TOPICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 252. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 253. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 254. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 255. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 256. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 258. AUSTRALIA SMALL-MOLECULE APIS MARKET SIZE, BY DISTRIBUTOR SALES, 2018-2030 (USD MILLION)
TABLE 259. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 260. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY FULL SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 261. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY HALF-SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 262. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 264. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 265. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 266. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 267. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 268. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY BIOTECH PROCESSES, 2018-2030 (USD MILLION)
TABLE 269. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 270. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 271. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY INJECTABLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 272. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY ORAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 273. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY TOPICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 274. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 275. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 276. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 277. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 278. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 280. CHINA SMALL-MOLECULE APIS MARKET SIZE, BY DISTRIBUTOR SALES, 2018-2030 (USD MILLION)
TABLE 281. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 282. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY FULL SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 283. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY HALF-SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 284. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 285. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 286. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 287. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 288. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 289. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 290. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY BIOTECH PROCESSES, 2018-2030 (USD MILLION)
TABLE 291. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 292. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 293. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY INJECTABLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 294. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY ORAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 295. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY TOPICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 296. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 297. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 298. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 299. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 300. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 302. INDIA SMALL-MOLECULE APIS MARKET SIZE, BY DISTRIBUTOR SALES, 2018-2030 (USD MILLION)
TABLE 303. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 304. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY FULL SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 305. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY HALF-SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 306. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 307. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 308. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 309. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 310. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 311. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 312. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY BIOTECH PROCESSES, 2018-2030 (USD MILLION)
TABLE 313. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY INJECTABLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY ORAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY TOPICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 322. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 323. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY DIRECT SALES, 2018-2030 (USD MILLION)
TABLE 324. INDONESIA SMALL-MOLECULE APIS MARKET SIZE, BY DISTRIBUTOR SALES, 2018-2030 (USD MILLION)
TABLE 325. JAPAN SMALL-MOLECULE APIS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 326. JAPAN SMALL-MOLECULE APIS MARKET SIZE, BY FULL SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 327. JAPAN SMALL-MOLECULE APIS MARKET SIZE, BY HALF-SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 328. JAPAN SMA

Companies Mentioned

  • AbbVie Inc.
  • Agilent Technologies, Inc.
  • Alacrita Holdings Limited
  • Albemarle Corporation
  • Aspen Group
  • Astrazeneca PLC
  • Aurobindo Pharma Limited
  • Bachem Holding AG
  • Bio-Rad Laboratories, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Cambrex Corporation by Permira funds
  • Carlyle Group
  • Charles River Laboratories International, Inc.
  • Deciphera Pharmaceuticals, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd,
  • Gilead Sciences, Inc
  • GlaxoSmithKline PLC
  • Koninklijke DSM N.V.
  • Lonza Group AG
  • Merck KGaA
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Continuous Manufacturing For Small Molecule APIs Market Size, Share & Trends Analysis Report by Equipment (Reactors, Crystallizers, Filtration Systems), Unit Operation, Type, End-use, Region, and Segment Forecasts, 2024-2030 - Product Image

Continuous Manufacturing For Small Molecule APIs Market Size, Share & Trends Analysis Report by Equipment (Reactors, Crystallizers, Filtration Systems), Unit Operation, Type, End-use, Region, and Segment Forecasts, 2024-2030

  • Report
  • 120 Pages
  • Global
From
Continuous Manufacturing For Small Molecule APIs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Continuous Manufacturing For Small Molecule APIs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
Therapeutics Market (2024 Edition): Analysis By Molecule Type (Biologics and Biosimilars, Small Molecules), By Therapeutic Area, By Region, By Country: Market Insights and Forecast (2020-2030) - Product Image

Therapeutics Market (2024 Edition): Analysis By Molecule Type (Biologics and Biosimilars, Small Molecules), By Therapeutic Area, By Region, By Country: Market Insights and Forecast (2020-2030)

  • Report
  • 224 Pages
  • Global
From
Nucleic Acid-Based Drugs Market by Drug Type (Antisense Oligonucleotides, DNA/RNA Aptamers, mRNA-Based Therapeutics), Molecule Type (Large Molecule, Small Molecule), Route of Administration, Therapeutic Area, End-User - Global Forecast 2025-2030 - Product Image

Nucleic Acid-Based Drugs Market by Drug Type (Antisense Oligonucleotides, DNA/RNA Aptamers, mRNA-Based Therapeutics), Molecule Type (Large Molecule, Small Molecule), Route of Administration, Therapeutic Area, End-User - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
U.S. Pharmaceutical Market Size, Share & Trends Analysis Report By Molecule (Biologics & Biosimilars, Conventional Drugs), By Product, By Type, By Route Of Administration, By Disease, By Age Group, By Distribution Channel, And Segment Forecasts, 2025 - 2030 - Product Image

U.S. Pharmaceutical Market Size, Share & Trends Analysis Report By Molecule (Biologics & Biosimilars, Conventional Drugs), By Product, By Type, By Route Of Administration, By Disease, By Age Group, By Distribution Channel, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • United States
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.